Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NICE Rejects Novartis’ Afinitor, Citing Irrelevant Evidence And High Cost

This article was originally published in The Pink Sheet Daily

Executive Summary

NICE has rejected Novartis’ Afinitor for breast cancer, citing excessive cost and shooting down three out of four evidence submissions.

You may also be interested in...



Despite Discount, High Price Again Fells Novartis’ Afinitor At NICE

Novartis’ discount for Afinitor in breast cancer has failed to convince NICE that the drug is cost-effective.

Novartis Cuts 2,000 Jobs In Switzerland And U.S., Pricing Pressures To Blame

Novartis intends to improve productivity and absorb pricing pressures by closing two Swiss manufacturing facilities and transferring some research to the U.S.

UK's New Cancer Drug Fund Might Not Alleviate Regional Access Disparities

The United Kingdom is creating a £600 million Cancer Drugs Fund to improve treatment access but a consultation document on the initiative is doing little to ease concerns about regional disparities in care.

Topics

Related Companies

UsernamePublicRestriction

Register

PS075430

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel